SECsense Logo

Vor Biopharma Inc. 8-K Filing: Key Updates for Investors on January 6, 2025

$VOR
Form 8-K
Filed on: 2025-01-08
Source
Vor Biopharma Inc. 8-K Filing: Key Updates for Investors on January 6, 2025

Based on the provided section of the financial report, here are the key extracted details and insights:

  1. Filing Type: The document is an 8-K filing, which indicates that it is a report of unscheduled material events or corporate changes that could be important to shareholders.
  2. Company Information:
  • Name: Vor Biopharma Inc.
  • State of Incorporation: Delaware (DE)
  • CIK Number: 0001817229 (Central Index Key used to identify the company in SEC filings)
  • IRS Employer Identification Number (EIN): 81-1591163
  1. Address:
  • 100 Cambridgepark Drive, Suite 101, Cambridge, MA 02140
  • Phone Number: (617) 655-6580
  1. Stock Information:
  • Common Stock: $0.0001 par value per share
  • Ticker Symbol: VOR
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: January 6, 2025
  • End Date: January 6, 2025
  • The context indicates that this is a single day reporting period.
  1. XML and XBRL Information:
  • The filing uses the XBRL (eXtensible Business Reporting Language) format, which allows for more efficient and consistent reporting of financial data.
  • The schema reference is linked to "vor-20250106.xsd," indicating the specific structure of the data in the filing.

Insights:

  • The filing is likely to relay significant corporate news or changes that occurred on January 6, 2025, which could impact investors and market perception.
  • Vor Biopharma Inc. operates in the biopharmaceutical sector and is publicly traded, suggesting that it may be involved in innovative drug development or therapies.
  • The presence of a NASDAQ listing indicates a certain level of credibility and regulatory oversight, which may be appealing to investors.
  • The specific date of the filing suggests that the information is timely and relevant, possibly related to a material event that occurred on that date.

Overall, stakeholders should pay attention to this filing for potential updates on corporate developments, financial performance, or other critical information that could influence the company's stock value.